PSP 007
Alternative Names: PSP-007Latest Information Update: 28 Jan 2024
At a glance
- Originator Prosit Sole Biotechnology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Phenylketonuria
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Phenylketonuria in China
- 24 Jun 2021 Prosit Sole Biotechnology plans a phase I trial for Phenylketonuria in 2022 (Prosit Sole Biotechnology website, June 2021)
- 24 Jun 2021 PSP 007 is available for licensing as of 24 Jun 2021. http://www.prositsole.com/index.php?catid=38